Total
0
Shares
Little Green Pharma (ASX:LGP) wins tender to supply medicinal cannabis for national French trial
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Little Green Pharma (LGP) has won a government tender to be a primary supplier of medicinal cannabis oils for a national trial in France
  • The two-year trial will test the efficacy, safety and quality of medicinal cannabis products in up to 3000 patients
  • As part of the trial, LGP will partner with leading pharmaceutical distributor, Intsel Chimos, who will undertake batch-release, distribution, medical information and drug safety obligations
  • Little Green Pharma will be responsible for manufacturing and supplying its medicines into France at its own cost
  • Ultimately, if the trial is successful, it may lead to the legalisation of medicinal cannabis in France — providing LGP with a "first-mover advantage"
  • Company shares are up 11.2 per cent and trading at 64.5 cents

Little Green Pharma (LGP) has been selected as a primary supplier of medicinal cannabis oils for a national trial in France.

Since 2018, the French National Agency for the Safety of Medicines and Health Products has been developing the tender for this two-year trial. The trial is aimed at testing the efficacy, safety and quality of medicinal cannabis products in up to 3000 patients.

These patients will have varying conditions such as refractory neuropathic pain, drug-resistant epilepsy, intractable symptoms linked to cancer or anticancer treatment, palliative situations, or painful spasticity from multiple sclerosis or other issues within the central nervous system.

Ultimately, if the trial is successful, it may lead to the legalisation of medicinal cannabis in France.

The medicinal cannabis trial is in partnership with Intsel Chimos, a leading pharmaceutical distributor and recognised hospital partner in France.

Since 1966, the French company has specialised in importing and distributing medicines to hospitals and dispensaries across France.

Intsel Chimos' role within the partnership involves undertaking batch-release, distribution, medical information and drug safety obligations. Meanwhile, LGP will be responsible for manufacturing and supplying its medicines into France at its own cost.

"We are very proud of our partnership's success in the French national tender and see this tender win as strong evidence of LGP successfully implementing its export-led global sales strategy and demonstrating the benefits of Australian Good Manufacture Practices (GMP) quality manufacturing in global pharmaceutical markets," Little Green Pharma Managing Director Fleta Solomon said.

Fleta also congratulated Intsel Chimos for developing a competitive bid for the tender and is looking forward to working together.

"We trust this marks the beginning of a long and rewarding partnership as we look to grow and cement our reputation amongst French patients and prescribers as a world-class medicinal cannabis supplier," she said.

Significantly, this tender provides Little Green Pharma with a "first-mover advantage" in case medicinal cannabis does end up being legalised in France after the trial.

Company shares are up 11.2 per cent and trading at 64.5 cents at 1:31 pm AEDT.

LGP by the numbers
More From The Market Herald
Orthocell (ASX:OCC) - Chief Scientific Officer, Minghao Zheng - The Market Herald

" Orthocell (ASX:OCC) has breakthrough tissue engineering study published in US

Creso Pharma (ASX:CPH) could receive up to $17.4 million in extra funding

" Creso Pharma (ASX:CPH) ends June quarter with revenue growth

Creso Pharma (CPH) has ended the June quarter with $1.63 million worth of generated revenue, an 18 per cent increase on its Marc…
Incannex Healthcare (ASX:IHL) - Chief Medical Officer, Dr Sud Agarwal - The Market Herald

" Incannex Healthcare (ASX:IHL) has a progressive fourth quarter

Incannex Healthcare (IHL) has spent the fourth quarter progressing its cannabinoid pharmaceutical products and psychedelic medicine therapies.
BARD1 Life Sciences (ASX:BD1) - CEO, Leearne Hinch - The Market Herald

" BARD1 Life Sciences (ASX:BD1) updates the market on Q4

BARD1 Life Sciences (BD1) has reported advances across its sales, business development and commercialisation activities over the June quarter.